Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery platform company "HitGen" to accelerate the discovery of new drug candidates for a FIC novel cancer therapeutics program Aims to strengthen its oncology portfolio with a novel drug candidate for newly identified hits from HitGen's proprietary DEL that are expected to exhibit potent anticancer activity CHENGDU, China , Aug. 22, 2024 /PRNewswire/ -- Bridge Biotherapeutics ("Bridge", KQ288330), a clinical-stage biotech company, announced that it has entered into a joint research agreement with HitGen Inc. ("HitGen", SSE: 688222.
SH), a Chinese drug discovery platform company. This collaboration builds on successful initial hit finding and identification work from HitGen's DNA-encoded library (DEL), aiming to further develop the novel hits as promising drug candidates for cancer. Bridge plans to strengthen its existing oncology portfolio, which is centered on EGFR inhibitors for lung cancer treatment, through new anticancer drug candidates targeting undisclosed targets.
Over the past year, the company has established its own analytical methods through preliminary research to discover new targeted anticancer drugs that are expected to show high anticancer effects across various cancer types. With the launch of this joint research with HitGen, it is anticipated that the derivation of effective substances, optimization, and securing of lead compounds will progress rapidly within the next yea.